摘要
目的观察健脾解毒方对不可切除胰腺癌二线及以上患者生存期及安全性的影响.方法回顾性分析2023年1月-2025年12月于我院中西医结合肿瘤科、肿瘤内科住院的不可切除胰腺癌二线及以上治疗患者共64例,根据是否使用健脾解毒方分为观察组及对照组,观察组采用健脾解毒方联合西医常规抗肿瘤治疗(共30例),对照组仅采用西医常规抗肿瘤治疗(共34例).观察两组患者总生存期(Overall Survival,OS)、无进展生存期(Progression-Free Survival,PFS)、客观缓解率(Objective Response Rate,ORR)、肿瘤控制率(Disease Control Rate,DCR)和不良反应情况.结果观察组的中位OS为8个月[95%置信区间(Confidence Interval,CI):7.60~8.40],中位PFS为5.75个月(95%CI:5.53~6.47),对照组的中位OS为6个月(95%CI:5.78~6.23),中位PFS为3个月(95%CI:2.35~3.65).两组中位OS及PFS比较,差异均具有统计学意义(P<0.05).ORR比较,两组差异无统计学意义(P>0.05).DCR比较,两组差异有统计学意义(P<0.05).观察组乏力、腹泻、厌食及贫血发生率均显著低于对照组,差异具有统计学意义(P<0.05).结论健脾解毒方可以提高不可切除胰腺癌二线及以上患者DCR,延长OS和PFS,且可以降低不良反应发生率,提高患者的生活质量.
Objective To evaluate the effect of Jianpi Jiedu Decoction on survival and safety in patients with unresectable pancreatic cancer receiving second-line or later treatment.Methods A retrospective analysis was conducted on 64 patients with unre-sectable pancreatic cancer who received second-line or higher treatment in the Department of Integrated Traditional Chinese and West-ern Medicine Oncology and the Department of Medical Oncology of our hospital from January 2023 to December 2025.These patients were divided into an observation group and a control group based on whether they received Jianpi Jiedu Formula.The observation group received Jianpi Jiedu Formula combined with conventional Western antitumor therapy(n=30),while the control group received only conventional Western antitumor therapy(n=34).The overall survival(OS),progression-free survival(PFS),objective response rate(ORR),disease control rate(DCR),and adverse drug reactions were observed between the two groups.Result The median overall survival(OS)in the observation group was 8 months[95%confidence interval(CI):7.60~8.40],and the median progression-free survival(PFS)was 5.75 months(95%CI:5.53~6.47).In the control group,the median OS was 6 months(95%CI:5.78~6.23),and the median PFS was 3 months(95%CI:2.35~3.65).Comparisons of median OS and PFS between the two groups were statistically significant(P<0.05).The overall response rate(ORR)showed no statistically significant difference between the two groups(P>0.05).However,the disease control rate(DCR)differed significantly between the two groups(P<0.05).The inci-dence of fatigue,diarrhea,anorexia and anemia in the observation group was significantly lower than that in the control group,with sta-tistically significant differences(P<0.05).Conclusion The Jianpi Jiedu Formula can improve the DCR in patients with unresectable pancreatic cancer who have received second-line or later treatment,prolong overall survival(OS)and progression-free survival(PFS),reduce the incidence of adverse reactions,and enhance patients'quality of life.
作者
朱治法
郑磊
于瀚卿
张梅
ZHU Zhi-fa;ZHENG Lei;YUHan-qing(Department of Integrated Traditional and Western Medicine In Oncology,The First Affiliaed Hospital of Anhui Medical University,Hefei 230022,China;Department of Oncology,The First Affiliated Hospital of Anhui Medical University,Hefei 230022,China)
出处
《肝胆外科杂志》
2026年第1期38-43,共6页
Journal of Hepatobiliary Surgery
基金
第三批安徽省名中医学术经验继承工作(编号:皖中医药秘[2025]10号)
张梅安徽省名中医工作室建设项目(编号:皖中医药发展秘[2022]25号)。
关键词
不可切除胰腺癌
健脾解毒方
中西医结合疗法
疗效观察
unresectable pancreatic cancer
Jianpi Jiedu Decoction
integrated traditional Chinese and western medicine therapy
efficacy observation
